(Q53195496)

12 May 2018

title

Individually tailored toxicity-based 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy of metastatic breast cancer. (English)

1 reference

12 May 2018

1 reference

6

Peter Nygren

1 reference

12 May 2018

5

Carl Blomqvist

1 reference

12 May 2018

Henrik Lindman

1

1 reference

12 May 2018

Gunnar Aström

2

1 reference

12 May 2018

Johan Ahlgren

3

1 reference

12 May 2018

Kenneth Villman

4

1 reference

12 May 2018

Jonas Bergh

7

1 reference

12 May 2018

publication date

1 January 2007

1 reference

12 May 2018

published in

Acta Oncologica

1 reference

12 May 2018

volume

46

1 reference

12 May 2018

page(s)

165-171

1 reference

12 May 2018

issue

2

1 reference

12 May 2018

A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma

cites work

1 reference

https://api.crossref.org/works/10.1080%2F02841860600871087

A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860600871087

High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860600871087

Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860600871087

How to calculate the dose of chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860600871087

A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860600871087

Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860600871087

Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860600871087

Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860600871087

Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860600871087

Reporting results of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860600871087

Quality of life assessment in clinical trials--guidelines and a checklist for protocol writers: the U.K. Medical Research Council experience. MRC Cancer Trials Office.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860600871087

Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860600871087

Dosage of adjuvant G-CSF (filgrastim)-supported FEC polychemotherapy based on equivalent haematological toxicity in high-risk breast cancer patients. Scandinavian Breast Group, Study SBG 9401.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860600871087

Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860600871087

The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860600871087

High dose, dose-intensive chemotherapy with doxorubicin and cyclophosphamide for the treatment of advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F02841860600871087

10.1080/02841860600871087

21 January 2018

Identifiers

DOI

1 reference

12 May 2018

PubMed ID

17453364

1 reference

12 May 2018